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Abstract 
The importance of the blood-brain barrier (BBB) in maintaining brain homeostasis 
cannot be better appreciated than during disease states, where disruption of its function is 
associated with dramatic detrimental clinical outcome. For decades, neuroscientists and 
neurobiologists investigated most neurological diseases under the prism of a neuro-
centric view, considering the contribution of non-neural components of the CNS (BBB, 
choroid plexus) negligible or even irrelevant. However, recent reviews have highlighted 
the importance of BBB breakdown in major neurological diseases.  
Hypoxia, as well as hypoxia/reoxygenation, is a key component of many neurological 
diseases and has been shown to significantly contribute to barrier disturbance and 
dysfunction. Since the master regulator of the hypoxic response, hypoxia inducible factor 
1 (HIF-1), is a key determinant for adaptation of cells and tissues to oxygen deprivation, 
it is likely that this transcription factor also plays a key role in barrier permeability. The 
possible future use of HIF-1 stabilizers for treatment of diseases characterized by oxygen 
deprivation to increase neuronal/cell survival means this question is now very pertinent. 
This review will focus its attention on the role of HIF-1 in BBB breakdown following 
hypoxic/ischemic injury and the implications for such therapies in a clinical setting. 
1. The blood-brain barrier (BBB) 
1.1. Introduction to the blood-brain barrier (BBB) An overview 
The central nervous system (CNS) constitutes one of the most important systems present 
in vertebrates, tightly regulating both vegetative and cognitive functions. In vertebrates 
most of the CNS is formed by neurons and glial cells (e.g. astroglia, oligodendrocytes 
and microglia). Due to their excitatory nature and their inability to further divide, neurons 
require a chemically defined and stable extracellular environment, sheltered from any 
sudden changes in composition. The ability to maintain such a microenvironment is 
achieved exclusively by the presence of the blood-brain barrier (BBB). The first 
documented description of the BBB was attributed to Paul Ehrlich [1] at the end of the 
19th Century, as he described the absence of chemical dye penetration within the CNS. 
However, the cellular and molecular nature of the BBB remained unclear for more than 
80 years until the publication of two seminal studies by Reese and colleagues. In the first 
study [2], the authors described the presence of the barrier at cellular junction between 
brain endothelial cells (ECs) lining the cerebral vasculature. Later on, the same authors 
demonstrated the presence of “tight junction” (TJ) complexes between EC cell junctions 
that were responsible for the barrier phenotype [3]. 
Although the BBB denomination was originally limited to brain ECs, the current 
consensus rather defines it as a multicellular neurovascular unit [4, 5]. The BBB is 
formed by a monolayer of specialized brain ECs harboring TJs complexes at their cellular 
junctions. These brain ECs are in direct contact with brain pericytes [6, 7] and separated 
from the brain parenchyma by two layers of extracellular matrices (ECM). The inner 
layer is formed by the vascular basement membrane localized at the EC basolateral side 
and is shared with neighboring pericytes. The outer layer is formed by the glia limitans 
that surrounds or ensheaths the cerebral vascular tree. Interestingly, in larger vessels these 
two matrix layers may also be separated by a perivascular space and populated by 
perivascular cells, particular cell types capable of macrophage activity [8, 9]. The main 
function of this space remains unclear, however it appears to play an important role in 
neuroinflammatory diseases [10]. The glia limitans is formed by polarized astrocyte end-
feet processes that directly contact and cover the vast majority of the microvasculature 
[11]. Finally, neurons and microglia contact the brain microvessels although the specific 
nature of these additional interactions is also debated. 
 
 
1.2. The BBB: the gatekeeper of CNS homeostasis 
The BBB plays a crucial role in maintaining CNS homeostasis by acting as a formidable 
“gatekeeper”, regulating the entrance of any chemical and biological entities into the 
CNS and vice-versa. Firstly, the presence of very “tight” TJ complexes eliminates the 
passive diffusion of solutes across the endothelium. Secondly, non-selective transport of 
small solutes by pinocytosis is virtually inexistent as brain ECs have a very low pinocytic 
activity. Therefore, the entrance of nutrients (glucose, amino acids etc) through the BBB 
can only be achieved by the recruitment of specialized solute carriers	   [12]. In contrast, 
lipophilic compounds (e.g. drugs, poisons) may reach the brain parenchyma easily via 
passive diffusion although the majority of these compounds have only limited 
bioavailability since the BBB presents an array of various ATP-binding cassettes (ABC) 
efflux transporters such as P-glycoprotein (P-gp, ABCB1), breast cancer resistance 
protein (BCRP, ABCG2) and multidrug-resistant polypeptides (MRPs) at their cell 
surface [13-16]. These transporters are highly efficient in removal/efflux of any foreign 
substances that have managed to penetrate the vascular system from the circulating blood 
such as drugs and pharmaceutics. Substrates of these transporters have a broad diversity 
in their chemical structures, making it very difficult to predict whether a newly designed 
drug candidate may avoid the efflux pump - indeed current success rates are exceedingly 
low. In addition, brain ECs are also capable of drug metabolic activity by the presence of 
certain cytochrome P450 enzymes such including CYP1B1 and CYP2U1 [16] which may 
therefore further compromise the diffusion of any spared molecules. The ability of the 
BBB to efficiently metabolize, efflux or exclude the entrance of foreign substances to the 
brain means that it also represents a formidable obstacle for drug entry and treatment of 
brain pathologies. Taken together, the essential “gatekeeper” function of the BBB is a 
blessing and a curse for the CNS: it prevents entrance of harmful agents capable of 
severely compromising brain integrity but also prevents the entrance of pharmaceutical 
drugs that could restore neuronal function and promote repair mechanisms following 
injury. 
Accumulating experimental evidence supports the hypothesis that opening of the BBB 
triggers a chain of events leading to neuronal dysfunction and damage resulting in 
neurological disease [4, 5, 17-19]. When coupled with previous brain insults, additional 
BBB disruption could have serious detrimental consequences for patient outcome. 
 
 
1.3. Tight junction complexes: the CNS great wall 
Endothelial cells that line the cerebral capillaries form the anatomic basis of the BBB in 
higher organisms. Unlike the endothelium of other vascular beds, specialized cerebral 
microvessel endothelial cells have very low permeability due to the presence of highly 
organized junctional complexes called tight junctions (TJs). TJ complexes represent 
highly intimate cell contacts and ensure stringent regulation of CNS homeostasis by 
severe restriction of the paracellular diffusional pathway between the endothelial cells 
and substances and/or cells within the circulating blood. These complexes are located 
within specific TJ strands bordering the basolateral side and brain ECs present three 
major types of TJ proteins: occludin [20, 21], claudins [22-24] and junctional adhesion 
molecules (JAMs) [25]. Occludin, claudin and JAM interactions occur through 
homotypic interactions [26, 27] however recent suggestion of heterotypic occludin 
interactions additionally imply a certain plasticity and dynamism at the BBB [27]. 
Occludin is a 65kDa tetraspan membrane protein [20] encoded by the OCLN gene. Its 
expression is mostly restricted to epithelial and endothelial cells. Very interestingly, 
occludin-deficient animals did not present major barrier leakage even at the BBB [28]. 
However abnormal calcification around cerebral vasculature was noted in these mice 
suggesting that occludin may regulate diffusion of bivalent cations such as calcium or 
magnesium. It is currently suggested that occludin plays a more permeability-regulating 
role by incorporating itself into the claudin-based strands (reviewed by [29]). The 
mechanism by which this occurs, and indeed the precise role(s) of occludin remain to be 
elucidated. Soon after cloning occludin the same authors described an additional class of 
TJ proteins called claudins [30]. Claudins are 20-27kDa tetradomain membrane proteins 
encoded by 23 different CLDN genes in human. Until now, four major claudins have 
been described at the BBB: claudin-1 [31], claudin-3 [32], claudin-5 [23] and claudin-12 
[33]. Evidence suggests that the claudins constitute the backbone of TJ strands at the 
BBB [29]. Increased expression of claudin 5 in rat brain capillary endothelial cells in 
vitro resulted in decreased monolayer permeability [34].  Unlike occludin-/- animals that 
showed no major vascular leakage, claudin-5-/- mice rapidly died after birth. Although no 
macroscopic vascular leakage was observed in these animals, Nitta and colleagues [33] 
noted an increased permeability to molecules with a molecular weight below 800 Da, 
suggesting that claudin-5 may infer the highest tightness to the “tight junctions”. The 
effect of deletion of other claudins on the BBB remains undocumented as these animals 
rapidly die in utero or during the early phase post-partum due to major epithelial lesions. 
Finally, the third class of protein described at the TJ complexes are represented by the 
JAMs [25]. Unlike occludin and claudins, JAMs belong to the immunoglobulin (IgG) 
superfamily and present two-extracellular IgG-like domains. Endothelial cells express all 
three different isoforms of JAMs: JAM-A, JAM-B and JAM-C [35]. JAMs play 
important roles in modulating barrier function in non-BBB endothelial cells as well as 
leukocyte-endothelial interactions. Although the importance of JAMs on BBB function 
remains largely unclear decreased JAM-A protein levels following BBB breakdown [36] 
and an increase in soluble JAM-A following BBB injury [37] suggests that JAM-A 
shedding may constitute a biomarker of BBB injury. 
Similar to other cell junction proteins, TJ membrane proteins interact with the actin 
cytoskeleton by soliciting the recruitment of zonula occludens proteins, classically 
referred as ZOs [38]. ZO proteins belong to the membrane associated guanylate kinase 
(MAGUKs), as they contain one or several PDZ, src-homology3 (SH3) and guanylate 
kinase (GK) domains. Both ZO-1 and ZO-2 expression at the BBB were demonstrated in 
the literature [39, 40], whereas proven ZO-3 expression remains undocumented. 
Interactions between ZO proteins and TJ membrane proteins occurs through their PDZ 
domains, whereas interactions with the cytoskeleton occurs through their C-terminus via 
their actin-binding regions (ABRs). In addition to these distinct domains, ZO proteins 
present several nuclear localization signals [38] suggesting a certain ability to shuttle 
between the cytoplasm and nucleus. Thus ZO proteins may act as transcription factors in 
addition to their structural scaffold function although the nature of ZO target genes and 
their relevance at the BBB remains unknown.  
 
 
2. Hypoxia and BBB function 
2.1. Hypoxia induces BBB disruption 
Reduction of oxygen levels such that supply fails to meet demand is termed hypoxia. 
Hypoxia is a strong stimulus for various physiological processes particularly during 
development but is also a major cause or consequence of injury and contributes to 
progression of many different diseases and pathologies. To ensure hypoxic survival cells 
must be able to adapt to oxygen deprivation and switch from aerobic to anaerobic 
metabolism until oxygen levels are restored to manageable levels. Notably resting oxygen 
levels, and sensitivity to oxygen deprivation, differ widely in various tissues and organs 
meaning that hypoxic exposure can have differential effects based on the tissue or cells 
being studied. The CNS constitutes a system that utilizes an unparalleled degree of 
physiological resources. With an average blood vessel surface of 10m2 [41] it solicits 15-
20% of total cardiac output and 20% of the arterial O2 input on its own under resting 
conditions [42]. In addition, it heavily relies on glucose as a source of energy by 
consuming ~20% of daily glucose intake [18]. Indeed, such extreme consumption 
underlies a heavy dependence of the cerebral tissue on constant O2 and glucose perfusion. 
Thus a rapid change in environmental or local O2 levels may result in dramatic 
consequences for CNS homeostasis and BBB integrity. Indeed hypoxia/ischemia may 
constitute the most frequent cerebrovascular event leading to BBB breakdown.  
The effects of hypoxia at the BBB have been extensively investigated. Hypoxia, as well 
as hypoxia/reperfusion stress and cerebral ischemia have been shown to alter localization 
and expression of the key junctional proteins ZO-1 and occludin at the BBB in both in 
vivo and in vitro BBB models, and correlates with increased paracellular permeability 
and edema [40, 43-46]. The effect of hypoxia on BBB function was also demonstrated to 
reduce claudin 5 expression levels and increase paracellular permeability of low 
molecular weight compounds after exposure of brain endothelial cells and retinal 
flatmounts to hypoxia [47]. The disruption of the BBB in hypoxic conditions is multi-
factorial and may involve factors such as enhanced production of vascular endothelial 
growth factor (VEGF), nitric oxide (NO) and inflammatory cytokines (reviewed by [48, 
49]. Increased cytokines and subsequent up-regulation of endothelial and neutrophil 
adhesion molecules lead to leucocyte adhesion and transmigration across the endothelium 
and the BBB creating a positive feedback loop that further enhances vascular damage 
[49]. 
Notably, ischemia or hypoxia-induced alterations in BBB TJs have not been observed in 
all studies. This may be related to differences in the severity of hypoxia within different 
areas of the brain following insult, the differential cell-response of surrounding cell types 
as well as the duration of the injury [50]. Understanding the inter-related and complex 
contributions of these parameters to the modulation of barrier function may be of 
significant relevance in the design of future therapeutics. 
 
 
2.2 Hypoxia-mediated HIF-1 signaling 
Hypoxia induces a variety of signaling pathways. The most widely studied mediators of 
the hypoxic response are the family of transcription factors known as hypoxia inducible 
factors (HIFs). There are 3 known members of the HIF family, namely HIF-1, 2 and 3 
with HIF-1 being the most well characterized and generally considered the master 
regulator of the hypoxic response. HIF-1, mediates many adaptive endogenous 
mechanisms during hypoxic brain injury by transcriptional activation of specific target 
genes that function to restore oxygen supply. 
HIFs are heterodimeric transcription factors consisting of an oxygen-inducible α subunit 
(HIFα) and an oxygen-independent subunit (HIFβ also known as ARNT) [51-53]. These 
subunits are differentially localised with HIFα being expressed in the cytoplasm whereas 
ARNT is a nuclear protein. Under normal conditions, i.e. in the presence of oxygen, the 
HIFα protein is constantly degraded due to hydroxylation of specific proline residues by 
enzymes called prolyl hydroxylases (PHDs) [54-57]. This modification leads to 
recognition by the von hippel lindau protein, ubiquitination and degradation by the E3 
ligase machinery. When oxygen is reduced and becomes limiting the PHD enzymes are 
inhibited. As a result HIFα is no longer degraded but accumulates and after 
phoshorylation is transported to the nucleus where it binds ARNT forming the functional 
HIF protein. Thereafter the heterodimer forms a complex with a number of other proteins 
and subsequently binds the hypoxic response element (HRE) in the promoter of target 
genes inducing their expression. To date a large number of HIF target genes have been 
identified, many being involved in the switch from aerobic metabolism to glycolysis as 
well as angiogenesis and erythrocytosis i.e. changes that reduce energy consumption and 
promote re-establishment of oxygen delivery thus facilitating cellular adaptation to 
oxygen deprivation, as well as a number of target genes involved in tissue repair [55, 58, 
59].  
Thus HIF-1 is largely considered to be essential for cellular survival during injury and 
has been reported to protect neurons from apoptosis caused by oxidative stress and focal 
cerebral ischemia [60-62]. Stimulation of HIF-1α upon hypoxic preconditioning or 
chemical induction of HIF-1α was also shown to induce HIF-1 target pro-survival genes 
such as VEGF and Epo resulting in increased cell survival [60, 63, 64] and 
neuroprotective effects (reviewed by [65]). HIF-1-induced angiogenesis and glycolytic 
metabolism also increased delivery of oxygen and nutrients that are critical for cell 
survival under hypoxic/ischemic conditions [63]. Furthermore, neuron-specific 
knockdown of HIF-1α was demonstrated to increase tissue damage and reduce survival 
of mice subjected to middle cerebral artery occlusion [66].  
Although HIFs are essential for cellular adaptation to reduced oxygenation, over the last 
few years it has become apparent that these transcription factors can act as double-edged 
swords. Indeed a wealth of contrasting data suggests that in addition to cellular adaptation 
and survival, HIFs also contribute to activation of cellular processes that lead to apoptosis 
and necrosis. Several groups have reported detrimental effects of HIF-1 in cerebral 
ischemia. For instance, Halterman et al. [67] reported that HIF-1α coordinated the 
activity of p53 in driving ischemia-induced delayed neuronal death instead of providing 
neuroprotection. HIF-1 was shown in vitro to mediate hypoxia-induced growth arrest and 
apoptosis [68] and regulate the expression of proapoptotic family members such as 
BNIP3 and caspase-3 that are increased following cerebral ischemia [69-72]. 
Furthermore brain-specific knockdown of HIF-1α reduced ischemic damage in knockout 
mice and was neuroprotective [73].  
Overall current data suggests that mild or acute hypoxia induces adaptive gene expression 
such as EPO, Glut1 and VEGF, whereas severe or sustained hypoxia HIF-1α can lead to 
activation of prodeath genes, such as BNIP3, COX2, or p53 stabilization (reviewed by 
[74]). Thus, HIF-1 can activate transcription factors and signaling pathways with both 
pro-death and pro-survival functions. The outcome of HIF-1 induction appears to be 
dependent on the duration [67], the pathological stimuli and the cell type in which it is 
induced [75]. Thus it is apparent that during oxygen deprivation cell-specific temporal-
spatial modulation of crucial HIF-1 signaling pathways is a key determinant of functional 
outcome. It is also essential to keep in mind that activation of the pathway under certain 
circumstances may also have negative outcomes – especially if the system is chronically 
activated/induced.  
Besides regulation by hypoxia, other signaling pathways can also modulate HIF 
activation. An example is evidence for a role of mitochondrial ROS in cellular oxygen 
sensing in at least some cell types [76]. The contribution of oxygen sensing, redox status 
and a variety of molecular factors and pharmacological agents to HIF stabilization has 
recently been reviewed by [74, 77]. 
 
 
3. HIF-1 signaling at the BBB 
3.1 Effect of HIF-1 on barrier permeability 
As stated above it is known that hypoxia compromises barrier integrity however the 
precise mechanisms that mediate barrier dysfunction remain largely unknown. The role 
of HIFs and their target genes in major cellular alterations and adaptations in response to 
oxygen deprivation suggests they may be instrumental modulators of BBB integrity. 
Indeed current data from our group and others suggest that HIF-1 is a likely mediator of 
barrier disruption. A possible role for either HIF-2 or 3 at the BBB is yet to be addressed. 
A study by Witt et al first suggested that transcription factors such as HIF-1 and NFκB 
are upstream mediators of TJ protein alterations during hypoxia and H/R, which may 
involve VEGF induction and expression. Indeed VEGF is a strong inducer of vascular 
permeability and increased VEGF levels positively correlate with changes in TJ 
redistribution of zona occluden-1 (ZO-1) and occludin, as well as with alterations in the 
actin cytoskeleton both in vivo and in vitro [78-81]. Yeh et al [82] subsequently 
demonstrated that 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole (YC-1) an inhibitor of 
HIF-1α was able to prevent increased permeability in adult rat brain endothelial cells in 
response to chemical hypoxia likely through inhibition of HIF-1α accumulation and 
VEGF production. Pretreatment with YC-1 also seemed to reduce ischemia/reperfusion-
induced increase of BBB permeability and HIF-1α accumulation in a rat in vivo model 
[82]. Elevation of HIF-1α was shown to be harmful in cerebral ischemia after 2 h of 
MCA occlusion, and inhibition of HIF-1α and VEGF by 2ME2 and D609 could protect 
against brain damage by reducing neuronal expression of BNIP3, and cleaved caspase 3 
during stroke [74]. Acute inhibition of HIF-1α (when administered within a 3 hour 
window) was also neuroprotective in neonatal hypoxic-ischemic injury by preserving 
BBB integrity and reducing brain edema [83]. Interestingly however most of the in vivo 
studies have not demonstrated convincingly that the crucial HIF modulation takes place 
in the endothelial cells, indeed in most cases the neurons were the most sensitive and 
robustly upregulated HIF-1.  
Very recently it was demonstrated that despite ameliorating ischemia-induced BBB 
disruption (determined by Evans blue leakage) YC-1 did not alter brain edema formation 
and significantly exaggerated ischemic brain damages in terms of infarct volume and 
mortality as evaluated by MRI and histological staining [84]. The data indicates that BBB 
protection resulting from HIF-1 inhibition by YC-1 contributes little to the overall brain 
tissue injury induced by cerebral ischemia – a finding that needs to be further 
investigated. However the study clearly implies that the presence of HIF-1 is critical in 
promoting neuronal survival during ischemia/reperfusion and HIF-1 modulation may 
have differential effects on ischemic outcome and BBB permeability.  
Notably, detrimental effects of HIF-1 on BBB function may not only be limited to stroke-
related events. In an in vivo model of traumatic brain injury (TBI) brain edema was 
significantly decreased after inhibition of HIF-1α [85]. HIF-1α activation in the brain of 
dystrophic mouse (model for Duchenne muscular dystrophy) was also suggested to be 
partly responsible for both BBB opening and increased angiogenesis through reduced 
protein levels and increased phosphorylation of ZO-1 as well as an up-regulation of 
VEGF and VEGFR-2 expression [86]. HIF-1α was shown to be involved in brain edema 
formation and BBB disruption via a molecular signaling pathway involving AQP-4 and 
MMP-9 in a subarachnoid hemorrhage model [87]. Other data strongly indicates that 
HIF-1 plays an important role in high glucose-induced BBB dysfunction. Upregulating 
HIF-1 activity by cobalt chloride increased the paracellular permeability of endothelial 
cells exposed to normal glucose whereas downregulating HIF-1 activity, by HIF-1α 
inhibitors and HIF-1α specific siRNA, ameliorated the redistribution of occludin and ZO-
1 and increased permeability induced by high glucose [88]. The involvement of HIF-1 in 
impaired junction assembly in the kidney has also been reported [76]. The precise 
mechanisms by which HIF-1 modulates TJ proteins are still to be fully elucidated. 
Hypoxia also rapidly stimulates cytoskeletal reorganisation in vitro [89, 90] and in vivo 
[48, 91] and attachment of TJ proteins to the actin cytoskeleton via accessory proteins 
[92] means that barrier permeability is also closely linked to such changes. Cytoskeletal 
rearrangements also result in cellular movement, such as endothelial migration leading to 
angiogenesis and retraction of astrocyte endfeet from vascular walls, both of which 
contribute to barrier breakdown. Whether these effects are HIF-1 dependent or 
independent is still to be addressed. 
 
 
3.2 Cell-specificity of HIF-1 mediated responses and their effect on BBB integrity 
Although current concepts advocate that conserved hypoxic adaptive mechanisms occur 
in many different cell types of the brain, specific temporal-spatial modulation of crucial 
pathways such as HIF signaling may be the key determinant of functional outcome. Thus 
the impact of activation of the HIF-1 pathway on the response of individual BBB cells 
and subsequent barrier function is a pertinent issue that needs to be tackled.  
Our studies clearly indicate that individual responses of barrier cells to O2 deprivation 
define the outcome of hypoxic injury and the integrity of the BBB [50, 93]. The 
contribution of HIF-1 induction by barrier modulating cells, astrocytes and pericytes as 
well as neurons themselves, to barrier stability is still a largely open question. Unlike 
many other cells, astrocytes are very resistant to hypoxic stress. We showed that severe 
oxygen deprivation is required to induce HIF signaling and modulate subsequent survival 
and proliferation in astrocytes [94]. However our data also indicates that VEGF induction 
during hypoxia in these cells likely occurs through HIF-1 dependent and independent 
mechanisms. Our current investigations advocate that pericytes are also hypoxia-resistant 
cells (unpublished data Engelhardt & Ogunshola et. al.) although fully comparable 
studies are still to be completed. Notably, astrocytes and pericytes have differential 
responses to hypoxia that are important for barrier regulation depending on the duration 
and severity of insult [50]. Although impairment and/or alteration of either astrocyte or 
pericyte function results in microvascular damage and accelerates neuronal death [49, 95, 
96], the contribution of activation of HIF-1 signaling in these cells to BBB leakage and 
central nervous system edema formation remains largely unknown. Interestingly it was 
recently demonstrated that although loss of HIF-1α function in neurons reduced neuronal 
viability during hypoxia, selective loss of HIF-1 function in astrocytes markedly 
protected neurons from hypoxic-induced neuronal death [75]. Notably, a systematic in 
vivo and in vitro investigation of cell-specific responses mediated via HIF-1 is warranted 
to provide detailed knowledge of physiological and pathological barrier modulation, and 
define future targets for development of rational therapeutic approaches that optimize 
recovery. 
 
 
4. HIF-1 stabilization as a therapeutic target 
Therapeutic activation of HIF-1 is likely to mimic, at least in part, the effects of hypoxia 
preconditioning. Indeed it has been suggested that certain protective agents in stroke may 
act via HIF induction (reviewed by [76]) but as is clear from the studies outlined above a 
major caveat is that not all consequences of HIF activation may be beneficial and some 
could even be deleterious. In general the therapeutic potential of development and use of 
small molecule HIF stabilizers (PHD inhibitors) to improve cell survival after injury is 
gaining popularity in many different fields. Such drugs could provide significant 
protection for a variety of different cells during injury and pathological situations such as 
stroke, TBI etc. Since the first indications are that HIF-1 may disturb barrier function the 
applications of such therapeutics must be treated with caution. Enhanced edema, and 
influx of other blood-borne molecules as a result of increased BBB permeability, will 
increase intra-cranial pressure and the transport of potentially detrimental substances into 
the brain parenchyma. Thus the adverse effects of reduced barrier integrity must be 
carefully assessed when administering HIF-1 stabilizing drugs. It must also be 
emphasized however that, as suggested by in vitro and in vivo studies, the duration of the 
stabilization of HIF-1 and the regions being targeted will likely be instrumental in 
obtaining a positive outcome during and after treatment and must also be taken into 
consideration. A number of reviews on the effects and use of PHD inhibitors and HIF-1 
stabilizers as therapeutics have recently been published [76, 97, 98]. 
On the other hand, it is feasible that such drugs could be used to induce a partial opening 
of the barrier and thus facilitate drug entry into the brain parenchyma. Such a strategy 
using combination therapies could have high benefit under particular scenarios. Indeed 
selective opening of the endothelium tight junctions to facilitate drug delivery to the brain 
is also an area of intense research since delivery of therapeutics to the CNS remains 
highly challenging [99, 100]. Of course the feasibility of such an approach, although very 
attractive, remains to be properly researched to ensure exploitation of the benefits of BBB 
modulation, while minimizing the potential damage. 
 
 
Conclusion 
Maintenance of BBB integrity and thus brain homeostasis is crucial for brain cells, and 
highly sensitive neurons in particular, to be able to function. During hypoxia/ischemia the 
BBB is compromised resulting in alterations that can have significant detrimental effects. 
Thus identification of the mediators of barrier dysfunction may provide not only 
important avenues to prevent barrier permeability but also perhaps ways to selectively 
modulate barrier function and facilitate the passage of protective drugs and therapeutics. 
Current data suggests that HIF-1 may represent such a mediator but more knowledge of 
the regulation of specific barrier properties during different injury paradigms and 
windows of opportunity is required. Better assessment of the positive versus the negative 
effects of acute versus chronic stabilization of HIF-1 is also needed. Overall considering 
its multifunctional role, differential effect on different cells and double-sword mode of 
action it seems unlikely that HIF-1 stabilization on its own will be the magic solution to 
improving brain cell survival after injury - but perhaps combination therapies will 
provide significant gains. As always many questions are still to be answered. 
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